EA201492259A1 - Терапевтические применения фракций мастиковой смолы - Google Patents

Терапевтические применения фракций мастиковой смолы

Info

Publication number
EA201492259A1
EA201492259A1 EA201492259A EA201492259A EA201492259A1 EA 201492259 A1 EA201492259 A1 EA 201492259A1 EA 201492259 A EA201492259 A EA 201492259A EA 201492259 A EA201492259 A EA 201492259A EA 201492259 A1 EA201492259 A1 EA 201492259A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mastic resin
therapeutic applications
resin fractions
mastic
relates
Prior art date
Application number
EA201492259A
Other languages
English (en)
Inventor
Задик Хазан
Original Assignee
Редженера Фарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Редженера Фарма Лтд. filed Critical Редженера Фарма Лтд.
Publication of EA201492259A1 publication Critical patent/EA201492259A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Изобретение относится к применению в терапии мастиковой смолы и соединений, обнаруженных в мастиковой смоле, включая полимер мирцена. Конкретнее, изобретение относится к способам лечения нарушенной неврологической функции при помощи композиций, содержащих полимер мирцена.
EA201492259A 2009-03-04 2010-03-04 Терапевтические применения фракций мастиковой смолы EA201492259A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15721509P 2009-03-04 2009-03-04

Publications (1)

Publication Number Publication Date
EA201492259A1 true EA201492259A1 (ru) 2015-04-30

Family

ID=42224206

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201492259A EA201492259A1 (ru) 2009-03-04 2010-03-04 Терапевтические применения фракций мастиковой смолы
EA201190168A EA021886B1 (ru) 2009-03-04 2010-03-04 Выделенная фракция мастиковой смолы

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201190168A EA021886B1 (ru) 2009-03-04 2010-03-04 Выделенная фракция мастиковой смолы

Country Status (12)

Country Link
US (4) US8956601B2 (ru)
EP (1) EP2403505B8 (ru)
CN (2) CN102413833B (ru)
AU (1) AU2010220056B2 (ru)
BR (1) BRPI1013223A2 (ru)
CA (2) CA2974805C (ru)
DK (1) DK2403505T3 (ru)
EA (2) EA201492259A1 (ru)
ES (1) ES2617875T3 (ru)
HU (1) HUE032032T2 (ru)
PL (1) PL2403505T3 (ru)
WO (1) WO2010100650A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578191A1 (en) 2009-03-04 2019-12-11 Regenera Pharma Ltd. Compositions of polymeric myrcene
WO2011051945A1 (en) * 2009-10-28 2011-05-05 Regenera Pharma Ltd. Therapeutic uses of oligomeric and polymeric monoterpenes
BR122019022461B1 (pt) 2010-09-07 2022-03-15 Regenera Pharma Ltd Processo para preparar uma fração ácida isolada de goma mástique
US20150246087A1 (en) * 2012-06-11 2015-09-03 Regenera Pharma Ltd. Extracts and therapeutic uses thereof
WO2015054696A1 (en) * 2013-10-11 2015-04-16 ABSORBezz LLC Animal health improvement composition and method
KR101645721B1 (ko) * 2014-12-30 2016-08-05 대전대학교 산학협력단 위장질환 예방 및 치료용 유향 함유 조성물
IL237621A0 (en) * 2015-03-08 2015-06-30 Regenera Pharma Ltd Use of isolated fractions of the gum goddess to treat optic neuropathy
CA2999820A1 (en) * 2015-09-24 2017-03-30 Regenera Pharma Ltd. Compositions comprising triterpenoids
DK3352742T3 (da) 2015-09-24 2022-01-10 Regenera Pharma Ltd Præparater omfattende triterpenoider til behandling af Alzheimers sygdom og Parkinsons sygdom
EP3509577A4 (en) * 2016-09-08 2020-04-08 Regenera Pharma Ltd. COMPOSITION WITH ACID EXTRACTS FROM RUBBER FITTING AND USES THEREOF FOR TREATING OPTICAL NEUROPATHY
US11207333B2 (en) 2016-09-08 2021-12-28 Regenera Pharma Ltd. Compositions comprising triterpenoids and uses thereof for treating optic neuropathy
KR102300227B1 (ko) * 2021-04-08 2021-09-09 주식회사 프롬바이오 매스틱 검 수용액을 포함하는 탈모 방지 및 발모 촉진용 화장료 조성물
KR102328824B1 (ko) * 2021-07-12 2021-11-23 주식회사 프롬바이오 수용화 매스틱 검과 감태나무 추출물을 이용한 발모 촉진 또는 탈모 억제용 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374957A (en) 1981-10-29 1983-02-22 Michigan Molecular Institute Triblock polymers of a monovinyl aromatic compound and myrcene
US4564718A (en) 1984-08-14 1986-01-14 The University Of Manchester Institute Of Science And Technology Functionally terminated polymers from terpene monomers and their applications
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPS63179908A (ja) 1987-01-22 1988-07-23 Japan Synthetic Rubber Co Ltd ミルセン重合体およびその製造方法
DE3820218A1 (de) 1988-06-14 1989-12-28 Osama L M Dr Med Dr Rer N Omer Phytotherapeutikum zur behandlung von depressivem syndrom
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US5506406A (en) 1993-05-17 1996-04-09 Atomic Energy Corporation Of South Africa Ltd. Method and apparatus for determining the concentration of a heavy element in a rock face
US5759569A (en) 1995-01-10 1998-06-02 The Procter & Gamble Company Biodegradable articles made from certain trans-polymers and blends thereof with other biodegradable components
US5714007A (en) 1995-06-06 1998-02-03 David Sarnoff Research Center, Inc. Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate
GR950100243A (el) 1995-06-28 1997-02-28 �. �����- �. ����� �.�.�. Χρησιμοποιηση της φυσικης μαστιχας χιου η του εξαγομενου εξ'αυτης φυσικου μαστιχελαιου η συνθετικων παραγωγων του για την παρασεκυη οδοντοκρεμας, οδοντικου διαλυματος, αποσμητικου στοματος, αντιηλιακων, προιοντων μαλλιων, καθως και καλλυντικων προιοντων.
JPH10130254A (ja) 1996-11-01 1998-05-19 Jumoku Seiri Kinousei Butsushitsu Gijutsu Kenkyu Kumiai ジヒドロクマリン系化合物およびエストロゲン作用剤
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
GR1003541B (el) 1999-05-11 2001-03-07 Αντιμικροβιακη και αντιμυκητιακη δραση του εξαγομενου απο τα κλαδια, φυλλα και καρπο της μαστιχας χιου -pistacia lentiscus var chia-, μαστιχελαιου, για χρηση σε καλλυντικες, φαρμακευτικες και παραφαρμακευτικεσς εφαρμογες καθως και στην παραγωγη οδοντοτσι
GR1003550B (el) 1999-09-22 2001-03-13 Σταθερο παρασκευασμα ισοεξυλοναφθαζαρινων με πεντα- και τετρα-κυκλικα τριτερπενια, συστατικα φυτικων ελαιορητινων και κομμεων
US6623728B2 (en) 2000-06-30 2003-09-23 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Cosmetic skin care compositions and containing gum mastic
US7056491B2 (en) 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
GR1003868B (el) * 2001-02-06 2002-04-19 Lavipharm S.A. Αξιολογηση των επουλωτικων, αντιοξειδωτικων και κυτταροστατικων ιδιοτητων της μαστιχας και των συστατικων της, και οι εφαρμογες τους
JP2004518707A (ja) 2001-02-13 2004-06-24 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム カロテノイドを充填されたリポソーム
US6534548B1 (en) 2001-10-02 2003-03-18 Kimberly-Clark Worldwide, Inc. Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria
AU2003241345A1 (en) 2002-05-01 2003-11-17 Lavipharm S.A. Use of mastic and its components for the control of microbial infections
JP2004083443A (ja) 2002-08-23 2004-03-18 Hideji Watanabe マスティックを用いた歯周病予防・治療用組成物及び歯周病予防・治療方法
US7232872B2 (en) 2002-12-20 2007-06-19 Exxonmobil Chemical Patents Inc. Polymerization processes
ATE469923T1 (de) 2002-12-20 2010-06-15 Exxonmobil Chem Patents Inc Polymere mit neuen sequenzverteilungen
US20050074509A1 (en) * 2003-10-02 2005-04-07 Data Medica Padova S.P.A. Cancer treatment using natural plant products or essential oils extracted from some pistacia species or components
CA2548430A1 (en) 2003-12-08 2005-06-16 Kenneth John Falk Plant materials extraction method
JP4831488B2 (ja) 2004-03-04 2011-12-07 独立行政法人理化学研究所 アイソタクチック３，４−イソプレン系重合体
WO2005112967A2 (en) 2004-05-19 2005-12-01 Balfour Marketing Corp. Anticancer activity of chios mastic gum
JP2008505685A (ja) 2004-07-06 2008-02-28 トランスファーマ メディカル リミテッド 経皮免疫処置用送達システム
EP1781235B1 (en) 2004-07-23 2013-12-25 Wholesome Life Science Co., Ltd. Anti-allergy activities of zingiber zerumbet (l.) smith
EP2263663A1 (en) * 2004-11-13 2010-12-22 Metaproteomics, LLC Compositions comprising curcuminoids and either alpha or beta acids for use in the treatment of diabetes
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
US20070148187A1 (en) * 2005-12-27 2007-06-28 Intact Enterprises, Inc. Mastic gum composition for use as a dietary supplement in humans and animals
CN100478335C (zh) * 2006-11-30 2009-04-15 上海力智生化科技有限公司 一种环氧月桂烯的制备方法
AR060847A1 (es) 2007-05-03 2008-07-16 Spannagel Lucia Antonia Formulacion a base de calendula, aloe y centella.
EP3578191A1 (en) 2009-03-04 2019-12-11 Regenera Pharma Ltd. Compositions of polymeric myrcene

Also Published As

Publication number Publication date
HUE032032T2 (en) 2017-09-28
AU2010220056B2 (en) 2015-04-02
BRPI1013223A2 (pt) 2017-09-26
US8956601B2 (en) 2015-02-17
EP2403505B8 (en) 2017-03-15
EA201190168A1 (ru) 2013-01-30
CN102413833B (zh) 2017-02-08
EA021886B1 (ru) 2015-09-30
US10251923B2 (en) 2019-04-09
US20150110902A1 (en) 2015-04-23
CA2754564A1 (en) 2010-09-10
CA2974805C (en) 2021-11-30
CN106619700A (zh) 2017-05-10
US20160287654A1 (en) 2016-10-06
US20190192594A1 (en) 2019-06-27
PL2403505T3 (pl) 2017-06-30
CN102413833A (zh) 2012-04-11
AU2010220056A1 (en) 2011-10-13
DK2403505T3 (en) 2017-03-06
WO2010100650A3 (en) 2010-11-25
CA2974805A1 (en) 2010-09-10
US9364509B2 (en) 2016-06-14
WO2010100650A4 (en) 2011-02-03
CA2754564C (en) 2017-09-12
ES2617875T3 (es) 2017-06-20
US20120003175A1 (en) 2012-01-05
WO2010100650A2 (en) 2010-09-10
EP2403505A2 (en) 2012-01-11
EP2403505B1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
EA201492259A1 (ru) Терапевтические применения фракций мастиковой смолы
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201001372A1 (ru) Формы рифаксимина и их применение
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201001639A1 (ru) Композиции и способы их получения и применения
PH12014500053A1 (en) Proteasome inhibitors
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
UA107783C2 (en) Isoindoline compounds for use in treating cancer
AU2011328009A8 (en) Compounds and methods for treating pain
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
CO6571886A2 (es) Antagonistas de pcsk9
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
EA201170349A1 (ru) Модуляторы mif
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
IN2012DN00971A (ru)
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119